https://www.thebodypro.com/category/dolutegravir-tivicay

Dolutegravir (Tivicay)

The Latest

Ricardo Diaz
Conference Coverage

Researcher Behind "Brazil Patient," the Latest HIV Remission Case, Explains How It Happened

The international news story that broke at AIDS 2020, explained by the lead researcher.

By Terri Wilder, M.S.W.
Ricardo Diaz, M.D. (top left) shares findings regarding a potential new HIV remission case in a virtual press conference during the 23rd International AIDS Conference on July 7, 2020.
Conference Coverage

HIV Clinical Research Highlights From AIDS 2020, the 23rd International AIDS Conference

COVID-19 or no, there was still plenty to learn at this year's virtual conference, including for U.S. clinicians seeking to improve the care and treatment they provide to their patients living with HIV.

By Myles Helfand
pregnant belly
Conference Coverage

Tempering Previous Concerns, Study Finds Dolutegravir Safest HIV Treatment During Pregnancy

New data shows the drug is not more likely to cause birth defects.

By Sony Salzman
aging face
Research

This Week in HIV Research: Playing Catchup on the Aging Front

March 12, 2020: The impact of age on viral suppression and immunologic recovery; chronic obstructive pulmonary disease risk among older PLWHIV; sex-based differences in older men vs. women; effect of aging on drug-drug interactions.

By Barbara Jungwirth and Myles Helfand
men on beach
News

This Week in HIV Research: Do You Believe in U=U?

Feb. 27, 2020: U=U perception vs. reality; frequency of incorrect self-reported viral load levels; how HIV transmission cluster predicts care continuum gaps; integrase inhibitor uptake and discontinuation.

By Barbara Jungwirth and Myles Helfand
three human skeleton models doing "see no evil, hear no evil, speak no evil"
News

This Week in HIV Research: Bone Concerns Aren’t Just for Older Folks

Jan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function.

By Barbara Jungwirth and Myles Helfand
Dolutegravir and Pregnancy photo illo
Features

Tsepamo Study Provides Critical Update on Neural Tube Defects and Dolutegravir

A lot of pregnancies in Botswana were anxiously followed after results from the Tsepamo study were revealed in late 2018. Updated data provide a medium-sized sigh of relief.

By David Alain Wohl, M.D.
The DAWNING Study photo illo
Features

DAWNING Study Casts New Light on the Details of Resistance

The findings will help providers manage patients who have known or potential resistance to NRTIs, but who we want to place on a simplified antiretroviral regimen.

By David Alain Wohl, M.D.
pill bottles on page full of data
Conference Coverage

Two-Drug HIV Regimen Works Well Except in People With Low CD4 Count, Study Finds

The combination of dolutegravir and lamivudine is effective for treatment-naive patients regardless of age, gender, or race, according to a new subgroup analysis of the GEMINI clinical studies.

By Sony Salzman
Pair of female feet on a bathroom scale
Conference Coverage

One Class of HIV Drugs Is Associated With Weight Gain. What's the Latest?

The question of whether INSTIs cause weight gain continues to be debated. This story draws together some research on which drugs are associated with weight gain or other metabolic changes.

By Sony Salzman